Successful experience of secukinumab and ixekizumab in treating erythrodermic psoriasis: A single-center, retrospective study

Erythrodermic psoriasis (EP) is a rare, severe, potentially life-threatening form of psoriasis. Laboratory results may present abnormalities such as leukocytosis, serum albumin loss, and elevated C-reactive protein. The assessment for laboratory data is lacking. This is a retrospective study of 28 cases of EP treated with secukinumab and ixekizumab. Except for skin restoration, initial management should include a full assessment, including an evaluation for systemic inflammation and correction of protein. The sustainability of inflammatory markers over 6 months are presented.